Caring for your brain can prevent cognitive decline and neurodegenerative diseases such as Alzheimer’s disease (AD). Celebrate Brain Awareness Week by learning strategies to keep your brain healthy.

SYNAPS Dx Releases Positive Budget Impact Results for DISCERN™ at International Conference on Aging Diseases and Elderly Care: Alzheimer’s Disease Diagnostic Projected to Save $4+ Million in Three Years

“We believe this investment continues to distinguish the accuracy of our biomarkers from all other diagnostics in Alzheimer’s Disease, since it is undoubtedly the first accurate, gold-standard autopsy-confirmed minimally invasive test for the definitive diagnosis of AD vs. other forms of dementia,” says Frank Amato, CEO and president, SDx. “DISCERN relies on three independently accurate biomarkers related to synaptic function and is well positioned to help address a number of key issues that payers, providers and patients face when it comes to getting a definitive diagnosis for AD early in the patient journey.”

Memory loss can be brought on by a number of treatable medical issues, including Lyme disease, vitamin deficiencies, thyroid issues, drug interactions and the various forms of dementia. Some of the conditions that are often mistaken for Alzheimer’s disease (AD) can easily be addressed with inexpensive interventions. Without a definitive diagnosis, however, it’s frustrating, expensive and overwhelming for patients and families, providers and payers to know how to proceed in the care journey.

DISCERN™ is the first autopsy-validated, highly accurate, minimally invasive test for the diagnosis of Alzheimer's Disease versus other forms of non-AD dementias and those with AD and other degenerative pathologies. This test is composed of three discrete assays that accurately assess the loss of synaptic activity in the brain due to AD and has been validated through biopsy. What’s more, the AD test’s assays have demonstrated >95% sensitivity and specificity.

DISCERN’s assays have demonstrated >95% sensitivity and specificity. It also identifies the Alzheimer’s Disease-specific degeneration biomarker for a definitive diagnosis, differentiates AD from other non-AD dementias and identifies those with AD in addition to other degenerative pathologies.

An early Alzheimer’s Disease diagnosis allows patients to start clinical interventions sooner, saving time, money, and the despair of caregivers and patients not knowing what is happening medically. Early diagnosis also gives patients the chance to have a say in their care.

Given that there are approximately 500,000 new cases of dementia each year in the United States, with about two million patients in years 0-3 of the disease at any given time, this opens a path for treatment earlier in the patient journey.

Accelerates Commercialization of DISCERN™: First Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease

SynapsDx is excited to collaborate with the MTC to bring about valuable innovations that can save lives and improve quality of life. SynapsDx is focused on bringing diagnostic solutions to people living with Alzheimer’s disease (AD), a type of dementia that affects memory, thinking and behavior. AD accounts for 60-80% of dementia cases and is not considered a normal aspect of aging.